Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is projected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $155.7920 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.49 on Wednesday. The business has a fifty day simple moving average of $31.40 and a two-hundred day simple moving average of $27.45. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $32.56. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CPRX. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Stephens set a $32.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Robert W. Baird lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, Citigroup cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Advisory Services Network LLC acquired a new position in Catalyst Pharmaceuticals during the third quarter worth about $39,000. Quarry LP bought a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $40,000. Smartleaf Asset Management LLC boosted its stake in shares of Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of Catalyst Pharmaceuticals by 17.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 469 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at approximately $93,000. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).